Waive Diagnostics, a United States based precision health technology company, will establish its South Asia base in Gelephu Mindfulness City, with plans to build an advanced genetic testing laboratory and digital diagnostics platform.

The move places Bhutan at the centre of a growing regional shift towards data driven and preventive healthcare, while aligning with the GMC’s focus on mindfulness, long term wellbeing, and data sovereignty.

The announcement follows a three year framework agreement signed with the GMC Authority. The company will begin operations from the Gelephu Central Regional Referral Hospital, before expanding into a fully equipped genetic testing facility.

A different approach to diagnostics

Waive Diagnostics does not position itself as a conventional laboratory or hospital service.

Instead, it operates as a technology platform that integrates multiple layers of health data into a single patient history. This includes:

• Genetic testing results
• Clinical records
• Imaging data
• Toxicology reports
• Lifestyle patterns
• Traditional medicine inputs

This system connects directly with Bhutan’s electronic patient records, allowing doctors to view long term health patterns rather than isolated symptoms.

David Stefanish, Managing Partner of Waive Diagnostics, said the goal is to improve how decisions are made in healthcare.

“A rash today may be linked to an enzyme imbalance from years ago and your gene never changes. Without longitudinal data, a doctor only sees the present. We connect the past to the present,” he said.

The platform also digitises laboratory processes. Each sample and machine is tracked through an automated system, replacing manual registers and improving traceability.

Data protection and AI integration

A central feature of the project is data security.

The company plans to deploy patented data protection systems and what it describes as “quantum-proof blockchain” architecture to ensure that Bhutanese health data remains within the country and under national control.

Artificial intelligence will be used to analyse genetic and clinical patterns. This can help identify disease risks earlier and support preventive care.

For example, the system can flag a patient’s susceptibility to conditions such as stomach cancer and suggest lifestyle adjustments before symptoms appear.

Stefanish emphasised that clinical decisions remain with doctors.

Why Bhutan

The decision to base operations in Bhutan was influenced by both policy direction and cultural context.

Dr Alex Cahana, advisor to Waive Diagnostics and Druk Holding and Investments, described the alignment with Bhutan’s development philosophy.

“In some countries, there is too little testing because it is expensive while in others, there is too much testing because it makes money. What GMC represents is a middle path, bringing science together with spirit. If you are going to do mindful testing, you do it in the Mindfulness City,” he said.

He also reflected on Bhutan’s broader development approach.

“Bhutan is not poor. It is only cash-poor. Gross National Happiness loves people and uses things, while Gross Domestic Product loves things and uses people. The world needs Bhutan’s worldview,” he said.

Stefanish shared a similar perspective following his visit.

“When you arrive in Bhutan, there is something special, a spirit,” he said, noting the country’s blend of traditional medicine, spirituality, and modern clinical care.

Phased rollout and capacity building

The project will be implemented in stages.

Phase one

• Operate from the existing hospital laboratory in Gelephu
• Upgrade systems, workflows, and equipment standards
• Achieve international accreditation within four to six months

Phase two

• Introduce advanced genetic and molecular testing equipment
• Expand testing capabilities currently unavailable in Bhutan

Phase three

• Begin serving regional demand from neighbouring countries

Currently, Bhutan sends many diagnostic samples abroad. This often leads to delays and limited control over data.

“Right now, Bhutan sends samples abroad and does not know where the data goes. Here, data stays in Bhutan. Results that take months can come back in a few hours,” Stefanish said.

Training and long term vision

Training is a core component of the agreement.

• US based specialists will train Bhutanese laboratory professionals on site
• Selected Bhutanese technicians will receive overseas exposure
• The goal is to establish a fully Bhutanese run lab within 24 months

The partnership will also explore integration with Bhutan’s digital identity systems and national health infrastructure under GMC governance frameworks.

Waive Diagnostics estimates the South Asian diagnostics market at around USD 15 billion. The company aims to position GMC as a regional hub within two years of operation.

A measured step into future healthcare

The project reflects a broader shift in Bhutan’s development strategy, where technology is introduced alongside existing values rather than replacing them.

If implemented as planned, the initiative could reduce reliance on external laboratories, improve early diagnosis, and build local expertise in advanced medical science.

At the same time, it raises important questions about data governance, system integration, and long term sustainability, areas that will shape how the project evolves.

For now, the agreement marks a practical step towards a more connected and preventive healthcare system in Bhutan.